Genome editing’s most prominent personalities, including Nobel laureate and co-inventor of CRISPR Jennifer Doudna, PhD, and pioneer in bringing gene editing into the clinic Fyodor Urnov, PhD, have spent the past few years searching for a solution to a sobering realization: while science has advanced rapidly, the mechanism for transforming it into customized medicines has lagged behind. Although precise gene edits theoretically address thousands of rare genetic diseases, most remain commercially and operationally stranded. On January 9, 2026, Aurora Therapeutics, co-founded by Doudna and Urnov, was launched on an ambitious premise: build a repeatable, scalable way to develop mutation-specific gene-editing therapies, not one miracle case at a time, but many in parallel.

That enterprising vision comes into sharper focus through the lens of CEO Edward Kaye, MD, who brings decades of rare-disease drug development experience to the company. In an interview during the 2026 J.P. Morgan Healthcare conference, Kaye frames Aurora’s launch as a moment of convergence—advances in CRISPR engineering, AI-driven design, sequencing, and a maturing regulatory landscape finally make personalized gene editing viable at scale. Kaye, who previously was CEO at Stoke Therapeutics and CMO at Sarepta Therapeutics, is tasked with turning Doudna and Urnov’s scientific conviction into a practical reality by assembling the capital, talent, and development framework required to industrialize bespoke therapeutic development, manufacturing, and implementation. Aurora isn’t just chasing scientific firsts; it’s trying to build a durable engine for delivering gene-editing therapies to patients who have waited far too long for options.